Patients with Residual Triple-Negative Basal-Like Breast CancerStatus: open
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Treatment for Breast Cancer
This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin or carboplatin is more effective than capecitabine in treating patients with residual triple negative basal-like breast cancer.
SponsorsThis trial is sponsored by ECOG-ACRIN.
Interested in Clinical Trial?
Providers Associated With This Trial
- Daniel G. Cameron, M.D.Medical OncologistSenior Staff Medical Oncologist, Medical Oncology Service; Associate Professor of Interdisciplinary Clinical Oncology